EXHIBIT 99.1


               SIMULATIONS PLUS CEO TO WORK FROM HOME TEMPORARILY

                           BUSINESS AS USUAL EXPECTED

         LANCASTER, CA, FEBRUARY 9, 2004. Simulations Plus, Inc. (OTCBB: SIMU),
the leading provider of ADME absorption simulation and neural net
structure-to-property prediction software for pharmaceutical discovery and
development, today reported that Walt Woltosz, chairman and chief executive
officer, has sustained a back injury that will require him to work from home for
approximately three months.

         Woltosz stated, "I don't expect any disruption to any critical activity
as a result of my injury. My work is done very much by computer, telephone, and
meetings, as well as travel. I can continue to do all of these except the
travel, which averages one or two trips per month. Travel that I would have
normally done will now be done by other senior staff members until I am back on
my feet. I have been informed by my physician that in order to allow the
fractured vertebrae to heal properly without surgery, I should not sit or stand
for about 11 more weeks.

         "I wanted to issue this release in the interest of full disclosure, and
at the same time, to assure our shareholders that no noticeable effect on the
company or its business is expected."


ABOUT SIMULATIONS PLUS, INC.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM),
which are based on its proprietary software technologies. Simulations Plus,
Inc., is headquartered in Southern California and trades on the OTCBB under the
symbol "SIMU." For more information, visit our Web site at
www.simulations-plus.com.


SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
- With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: the ability of the Company to
book revenues and earnings as it expects for the current quarter, the ability of
the Company to maintain its competitive advantage, the general economics of the
pharmaceutical industry, the ability of the Company to attract and retain
sufficient scientific and technical staff to sustain its R&D and customer
support functions, and a sustainable market. Further information on the
Company's risk factors is contained in the Company's quarterly and annual
reports as filed with the Securities and Exchange Commission.

                                       ###